Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs.

Abstract

This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.